SCHEMBL2732912

SCHEMBL2732912

CON(C)C(=O)c1ccc2nonc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA3 P42263 1/20 0.46
GRIA4 P48058 1/20 0.46
MLYCD O95822 1/20 0.43
POLB P06746 3/20 0.43
ADORA3 P0DMS8 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA2B P29275 1/20 0.43
ADORA1 P30542 1/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
TAS1R2 Q8TE23 1/20 0.42
ENPP2 Q13822 2/20 0.41
EPHX2 P34913 1/20 0.39
PKM P14618 1/20 0.38
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1644909 0.79 POLB (0.56) MLYCDPOLBNPC1MAPTRAB9A
SCHEMBL1419919 0.78 NPC1 (0.50) MLYCDPOLBNPC1MAPTRAB9A
SCHEMBL30134027 0.77 POLB (0.44) MLYCDPOLBNPC1MAPTRAB9A
SCHEMBL562695 0.76 KMT2A (0.53) POLBADORA3ADORA2AADORA2BADORA1
SCHEMBL562384 0.76 POLB (0.52) GRIA3GRIA4POLBNPC1RAB9A
SCHEMBL562419 0.75 POLB (0.65) GRIA3GRIA4POLBNPC1RAB9A
SCHEMBL21129476 0.75 TAS1R3 (0.48) MLYCDPOLBNPC1RAB9ATAS1R3
SCHEMBL15088704 0.75 CTNNB1 (0.50) MLYCDPOLBNPC1RAB9ATAS1R3
SCHEMBL2733233 0.74 GRIA3 (0.54) GRIA3GRIA4POLBADORA3ADORA2A
SCHEMBL3734922 0.74 TAS1R3 (0.50) POLBNPC1MAPTRAB9ATAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10954232-B2 Pyrazole derivative as ALK5 inhibitor and uses thereof HANMI PHARMACEUTICAL CO., LTD. (KR) 2021-03-23 US disclosed
US-20190194198-A1 NOVEL PYRAZOLE DERIVATIVE AS ALK5 INHIBITOR AND USES THEREOF HANMI PHARMACEUTICAL CO., LTD. (KR) 2019-06-27 US disclosed
EP-2297133-B1 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS FORUM PHARMACEUTICALS INC (US) 2017-09-13 EP disclosed
EP-2297133-B1 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS FORUM PHARMACEUTICALS INC (US) 2017-09-13 EP disclosed
US-9265767-B2 1,2-disubstituted heterocyclic compounds FORUM PHARMACEUTICALS INC. (US) 2016-02-23 US disclosed
US-9265767-B2 1,2-disubstituted heterocyclic compounds FORUM PHARMACEUTICALS INC. (US) 2016-02-23 US disclosed
US-9265767-B2 1,2-disubstituted heterocyclic compounds FORUM PHARMACEUTICALS INC. (US) 2016-02-23 US disclosed
US-20150274706-A1 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS FMR LLC 2015-10-01 US disclosed
US-20150274706-A1 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS FMR LLC 2015-10-01 US disclosed
US-20150274706-A1 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS FMR LLC 2015-10-01 US disclosed
US-20120232265-A1 1,2-Disubstituted Heterocyclic Compounds ENVIVO PHARMACEUTICALS, INC. 2012-09-13 US disclosed
US-20120232265-A1 1,2-Disubstituted Heterocyclic Compounds ENVIVO PHARMACEUTICALS, INC. 2012-09-13 US disclosed
WO-2012058134-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2012-05-03 WO disclosed
US-8071595-B2 1,2-disubstituted heterocyclic compounds ENVIVO PHARMACEUTICALS, INC. (US) 2011-12-06 US disclosed
US-8071595-B2 1,2-disubstituted heterocyclic compounds ENVIVO PHARMACEUTICALS, INC. (US) 2011-12-06 US disclosed
US-8071595-B2 1,2-disubstituted heterocyclic compounds ENVIVO PHARMACEUTICALS, INC. (US) 2011-12-06 US disclosed
US-20100137317-A1 1,2-Disubstituted Heterocyclic Compounds ENVIVO PHARMACEUTICALS, INC. (US) 2010-06-03 US disclosed
US-20100137317-A1 1,2-Disubstituted Heterocyclic Compounds ENVIVO PHARMACEUTICALS, INC. (US) 2010-06-03 US disclosed
US-20100137317-A1 1,2-Disubstituted Heterocyclic Compounds ENVIVO PHARMACEUTICALS, INC. (US) 2010-06-03 US disclosed
WO-2009158393-A1 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS ENVIVO PHARMACEUTICALS, INC. (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232265-A1 1,2-Disubstituted Heterocyclic Compounds PDE12, PDE7A, PDE10A GRIA3 833/4885GRIA4 618/4885MLYCD 1547/4885
US-20150274706-A1 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS PDE12, PDE7A, PDE10A GRIA3 833/4885GRIA4 618/4885MLYCD 1547/4885
US-20190194198-A1 NOVEL PYRAZOLE DERIVATIVE AS ALK5 INHIBITOR AND USES THEREOF ALK, SMAD3, TGFBR1 GRIA3 2186/4885GRIA4 2382/4885MLYCD 1097/4885
US-20100137317-A1 1,2-Disubstituted Heterocyclic Compounds PDE12, PDE7A, PDE10A GRIA3 833/4885GRIA4 618/4885MLYCD 1547/4885
US-10954232-B2 Pyrazole derivative as ALK5 inhibitor and uses thereof ALK, SMAD3, TGFBR1 GRIA3 1886/4885GRIA4 2253/4885MLYCD 1182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.